Cargando…
Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone inju...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079270/ https://www.ncbi.nlm.nih.gov/pubmed/30109228 http://dx.doi.org/10.3389/fbioe.2018.00105 |
_version_ | 1783345237693825024 |
---|---|
author | Perez, Jose R. Kouroupis, Dimitrios Li, Deborah J. Best, Thomas M. Kaplan, Lee Correa, Diego |
author_facet | Perez, Jose R. Kouroupis, Dimitrios Li, Deborah J. Best, Thomas M. Kaplan, Lee Correa, Diego |
author_sort | Perez, Jose R. |
collection | PubMed |
description | Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis—AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration. |
format | Online Article Text |
id | pubmed-6079270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60792702018-08-14 Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects Perez, Jose R. Kouroupis, Dimitrios Li, Deborah J. Best, Thomas M. Kaplan, Lee Correa, Diego Front Bioeng Biotechnol Bioengineering and Biotechnology Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis—AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration. Frontiers Media S.A. 2018-07-31 /pmc/articles/PMC6079270/ /pubmed/30109228 http://dx.doi.org/10.3389/fbioe.2018.00105 Text en Copyright © 2018 Perez, Kouroupis, Li, Best, Kaplan and Correa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Perez, Jose R. Kouroupis, Dimitrios Li, Deborah J. Best, Thomas M. Kaplan, Lee Correa, Diego Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title | Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title_full | Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title_fullStr | Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title_full_unstemmed | Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title_short | Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects |
title_sort | tissue engineering and cell-based therapies for fractures and bone defects |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079270/ https://www.ncbi.nlm.nih.gov/pubmed/30109228 http://dx.doi.org/10.3389/fbioe.2018.00105 |
work_keys_str_mv | AT perezjoser tissueengineeringandcellbasedtherapiesforfracturesandbonedefects AT kouroupisdimitrios tissueengineeringandcellbasedtherapiesforfracturesandbonedefects AT lideborahj tissueengineeringandcellbasedtherapiesforfracturesandbonedefects AT bestthomasm tissueengineeringandcellbasedtherapiesforfracturesandbonedefects AT kaplanlee tissueengineeringandcellbasedtherapiesforfracturesandbonedefects AT correadiego tissueengineeringandcellbasedtherapiesforfracturesandbonedefects |